Newswise — January 10, 2023 – The recently introduced thulium fiber laser (TFL) does not improve the clinical outcomes of laser treatment for urinary stones compared to the standard for laser stone therapy, reports a randomized trial in The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
Despite its theoretical technical advances, the new study shows TFL has no significant clinical advantage over a modern high-power pulse modulated holmium-yttrium aluminum garnet (Ho:YAG) laser in ureteroscopic lithotripsy of stones. "Our findings suggest that either of these currently available laser systems can provide excellent clinical outcomes treating non-staghorn renal and ureteral calculi in skilled hands," comments lead author Christopher R. Haas, MD, of University of Wisconsin.
First clinical comparison of TFL and Ho:YAG lasers
Approved by the US Food and Drug Administration in 2019, the TFL is a relatively new alternative to Ho:YAG energy for laser lithotripsy of urinary stones. Introduced in the 1990s with technical refinements over the years, the Ho:YAG laser has been the gold standard of care for laser lithotripsy. In this minimally invasive procedure, laser energy is delivered through a fiber passed through a ureteroscope directly to the visualized stone to break up or "dust" stones into pieces small enough to pass down the ureter.
The TFL has lower voltage requirements, a theoretically faster ablation speed, and a wider range of frequency and energy settings that permit ultra-fine dusting settings compared to high-power Ho:YAG units. However, there is limited high-quality evidence to show that the TFL offers better clinical outcomes compared to modern high-power pulse modulated Ho:YAG systems.
The randomized controlled trial included 108 patients with urinary stones smaller than two centimeters located in the kidney and/or ureter undergoing outpatient surgery with ureteroscopy and laser lithotripsy. Patients were randomly assigned to treatment with the TFL or a current-generation high-power pulse modulated Ho:YAG laser. Fifty-six patients received TFL treatment and 52 received Ho:YAG laser treatment. Patient and stone characteristics were similar between groups. The laser performance and clinical outcomes of operative time, complications, and stone free rate were compared.
Comparable results on key kidney stone treatment outcomes
The results showed that the two lasers required similar time to break up stones into passable fragments of one millimeter or less: an average of 19.9 minutes with the TFL and 21.4 minutes with the Ho:YAG laser. Both lasers also performed similarly on stones of different sizes, densities, and in different locations. Other important clinical outcomes were similar as well, including stone-free rate and any post-operative complication within 60 days. The Ho:YAG laser used less total energy and had improved efficiency, suggesting that the TFL requires more energy to produce comparable outcomes – although the clinical significance of this finding is unclear.
The two lasers also produced similar improvement on a standard measure of stone-related symptoms and quality of life (the Wisconsin Stone Quality of Life questionnaire [WISQOL]). On a zero-to-100 scale, average improvement was about 35 points for the TFL and 24 points for the Ho:YAG laser. In subjective assessments, surgeons rated the TFL as being more efficient overall and having less retropulsion (pushing stones backwards). A more stably positioned stone during lithotripsy (less retropulsion) may aid in making lithotripsy quicker and more successful.
Dr. Haas and colleagues note their findings differ from a previous study, which reported improved outcomes with the TFL. However, that study used an older non pulse-modulated Ho:YAG laser with lower power settings. The authors note that the optimal power settings for lithotripsy using the TFL have yet to be established.
"This randomized clinical trial suggests no significant clinical advantage of one laser technology over the other," Dr. Haas and coauthors conclude. "As both technologies are safe and highly effective, surgeon and institutional preference is the best approach when selecting one or the other."
###
About The Journal of Urology®
The Official Journal of the American Urological Association (AUA), and the most widely read and highly cited journal in the field, The Journal of Urology® brings solid coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of urology. This premier journal presents investigative studies on critical areas of research and practice, survey articles providing brief editorial comments on the best and most important urology literature worldwide and practice-oriented reports on significant clinical observations. The Journal of Urology® covers the wide scope of urology, including pediatric urology, urologic cancers, renal transplantation, male infertility, urinary tract stones, female urology and neurourology.
About the American Urological Association
Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 23,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health care policy. To learn more about the AUA visit: www.auanet.org
About Wolters Kluwer
Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.
Wolters Kluwer reported 2021 annual revenues of €4.8 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 20,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.
For more information, visit www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.
RSS